Stock Price Quote

AAREY DRUGS & PHARMACEUTICALS LTD.

NSE : AAREYDRUGSBSE : 524412ISIN CODE : INE198H01019Industry : Pharmaceuticals & DrugsHouse : Aarey
BSE66.01-0.99 (-1.48 %)
PREV CLOSE ( ) 67.00
OPEN PRICE ( ) 66.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 14687
TODAY'S LOW / HIGH ( )63.65 67.15
52 WK LOW / HIGH ( )31.3 100
NSE65.34-1.83 (-2.72 %)
PREV CLOSE( ) 67.17
OPEN PRICE ( ) 66.27
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 65.34 (10022)
VOLUME 673307
TODAY'S LOW / HIGH( ) 63.82 67.20
52 WK LOW / HIGH ( )31.35 100
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-05 1990
Management Info
Mihir R Ghatalia - Chairman Mihir R Ghatalia - Managing Director
Registered Office

Address E 34,M I D C ,Tarapur Boisar,
Thane,
Maharashtra-401506

Phone 02525 271049

Email info@aareydrugs.com

Website www.aareydrugs.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

03Jun Aarey Drugs & Pharmaceuticals informs
In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosur..
06Mar Aarey Drugs & Pharmaceuticals informs
Aarey Drugs & Pharmaceuticals has informed that the Board of Directo..
17Feb Aarey Drugs & Pharmaceuticals informs
Aarey Drugs & Pharmaceuticals has informed that the Board of Directo..
07Dec Aarey Drugs & Pharmaceuticals informs
Pursuant to Regulation 30 of the Listing Regulations, Aarey Drugs &..
06Nov Aarey Drugs & Pharmaceuticals informs
Aarey Drugs & Pharmaceuticals has informed that the meeting of the B..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit10.249999999999940.2400000000006
Gross Profit 14.8299999999999 61.0200000000006
Operating Profit 34.3599999999999127.110000000001
Net Sales 841.624739.43

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

CORONA Remedies (BSE)
peergroup  1437.20 (35.33%)
M.Cap ( in Cr)8789.93
Neuland Laboratories (BSE)
peergroup  16421.90 (2.15%)
M.Cap ( in Cr)21069.12
Procter&Gamble Healt (BSE)
peergroup  5675.85 (1.74%)
M.Cap ( in Cr)9421.56
Fredun Pharma (BSE)
peergroup  1660.40 (5.00%)
M.Cap ( in Cr)783.98
RPG Life Sciences (BSE)
peergroup  2372.25 (2.78%)
M.Cap ( in Cr)3923.47

Shareholding Pattern

NON-INSTITUTION 54.07%
PROMOTERS 44.8%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Aarey Drugs & Pharmaceuticals Ltd.

Aarey Drugs & Pharmaceuticals Ltd. was incorporated in the year 1990. Its today's share price is 66.01. Its current market capitalisation stands at Rs 187.17 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4739.43 Cr and Total Income of Rs.4837.57 Cr. The company's management includes Kailash Chand Jethlia, Bina Ghatalia, Anil Mandal, Lalit R Tulsiani, Chetan Kiritbhai Mehta, Nimit R Ghatalia, Mihir R Ghatalia, Mihir R Ghatalia.

It is listed on the BSE with a BSE Code of 524412 , NSE with an NSE Symbol of AAREYDRUGS and ISIN of INE198H01019. It's Registered office is at E 34,M I D C ,Tarapur BoisarThane-401506, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are DMKH & Co, Motilal & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.